The shorts got wind of something in the works otherwise why all the covering? If the CEO has something juicy and meaty to announce then IMHO the shares go to the $18 -$20 mark on a sneeze. This is a great poker game and the question is who has the best hand or is it all a bluff?
Recent CCCC News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/10/2026 11:17:23 AM
- C4 Therapeutics shares jump on expanded oncology collaboration with Roche • IH Market News • 04/09/2026 02:57:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/09/2026 11:07:35 AM
- C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs) • GlobeNewswire Inc. • 04/09/2026 10:59:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 02:45:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 02:45:44 PM
- C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma • GlobeNewswire Inc. • 03/25/2026 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/09/2026 08:20:02 PM
- C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/09/2026 08:01:00 PM
- Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types • PR Newswire (Canada) • 03/05/2026 02:00:00 PM
- Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types • PR Newswire (US) • 03/05/2026 02:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2026 12:49:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 12:09:49 PM
- C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights • GlobeNewswire Inc. • 02/26/2026 12:00:00 PM
- C4 Therapeutics to Participate in Upcoming March Conferences • GlobeNewswire Inc. • 02/23/2026 12:10:00 PM
- C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma • GlobeNewswire Inc. • 02/23/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 10:05:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 10:05:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 10:05:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 10:04:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 10:04:38 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/17/2026 06:45:15 PM
- C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 02/09/2026 09:01:00 PM
- C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 • GlobeNewswire Inc. • 02/04/2026 12:00:00 PM
